Dendritic Cell Cancer Vaccine for High-grade Glioma
Status:
Completed
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
A randomised, open-label, 2-arm, multi-centre, phase II clinical study with one group
receiving standard therapy with Temozolomide, radiotherapy, and Trivax; and a control group
receiving standard therapy with Temozolomide and radiotherapy only; after tumour resection of
at least 70% in both groups. The hypothesis is based on the assumption that time to
progression will be doubled in the treatment group.